

National Jewish Health[®] Breathing Science is Life.

Grant ID: 91661777 Final Outcomes Summary: Live Virtual Hybrid Activity

NTM Lecture Series for Providers

April 25-26, 2024

Final Live Outcomes Summary

Table of Contents

- Executive Summary (Slide 3)
- Marketing Strategies (Slide 4)
- Program Faculty (Slides 5-6)
- Quantitative Educational Impact Summary (Slide 7)
- Qualitative Educational Impact Summary (Slide 8)
- Level 1 Outcomes: Participation (Slides 9-10)
- Level 2 Outcomes: Satisfaction (Slide 11)
- Level 3/4 Outcomes: Knowledge and Competence (Slides 12-20)
- Level 4 Outcomes: Competence (Slides 21-22)
- Program Evaluation Results (Slides 23-24)
- Level 5 Outcomes: Performance (Slides 25-26)
- Accreditation (Slide 27)
- Patient Course Outcomes (Slides 28-30)



Executive Summary: Activity Details

Learning Objectives: Provider Course

- 1. Recognize the incidence and distribution of NTM disease
- 2. Identify the clinical manifestations of NTM disease
- 3. Differentiate the various types of NTM infections
- 4. Describe the guidelines for the diagnosis and treatment of NTM infections
- 5. Apply the latest evidence to decisions about pharmacologic and non-pharmacologic management of NTM


Learning Objectives: Patient Course

- 1. Summarize the incidence, prevalence and clinical manifestations of NTM and bronchiectasis
- 2. Review current and emerging treatment options for NTM and associated comorbidities
- 3. Identify strategies to embrace a healthy lifestyle and minimize side effects
- 4. Discuss available resources and support networks to enhance overall quality of life for NTM patients and their families

The **2024 Annual NTM Lecture Series for Providers and Patients** was held both in-person and virtually. The first two days of the conference was focused on education for providers, and the final day educated patients and their families. Faculty included key opinion leaders from National Jewish Health and institutions across the U.S. who delivered lectures with opportunity for question and answer after each presentation. Both components of the conference were recorded and endured online for paid registrants.

Target Audience: Pulmonologists, infectious disease physicians, family and internal medicine physicians, physician assistants, advanced practice nurses, registered nurses, and other health care professionals who diagnose and treat patients with NTM

Marketing Strategies



Targeted emails to NJH database and purchased specialty lists





With over 86,000 cases of Nontuberculous Mycobacterial (NTM) in the United States, the rates of infection are increasing. NTM infections are under recognized and cause significant morbidity and mortality Video recordings will be available to all registered attendees after the program for on-demand viewing. Don't be left in the dark. Master diagnosis and treatment of NTM to help wrice midmer vending baby is bash im their health

> NTM Lecture Series for Providers April 25-26, 2024

Offered in-person and Zoom

National Jewish Health | Molly Blank Conference Center | Denver, Colorado VIEW THE NTM LECTURE SERIES FOR PROVIDERS AGENDA

REGISTER FOR NTM LECTURE SERIES FOR PROVIDERS

NTM Conference Co-Chairs:



Charles L. Daley, MD Professor and Chief Division of Mycobacterial & Respiratory Infections Department of Medicine National Jewish Health Denver, Colorado



Shannon H. Kasperbauer, MD Associate Professor of Medicine Division of Nycobacterial and Respiratory Infections National Jewish Health University of Colorado Denver Denver, Colorado





Thank you to all the faculty who make this program possible!

Edward D. Chan, MD

Staff Physician National Jewish Health Pulmonologist, Rocky Mountain Regional VA Medical Center

Charles Daley, MD (Program Co-Director)

Chief, Division of Mycobacterial and Respiratory Infections Professor of Medicine National Jewish Health

Jared J. Eddy, MD Assistant Professor of Medicine Director of Infection Prevention & Antimicrobial Stewardship Division of Mycobacterial & Respiratory Infections National Jewish Health

David E. Griffith, MD Professor of Medicine Division of Mycobacterial & Respiratory Infections National Jewish Health

Jennifer Honda, PhD, ATSF Associate Professor Director, NTM Center at Tyler University of Texas Health Science Center at Tyler

Shannon Kasperbauer, MD

(Program Co-Chair) Associate Professor of Medicine Division of Mycobacterial and Respiratory Infections National Jewish Health

Reeti Khare, PhD Director, Infectious Disease Laboratory Associate Professor Advanced Diagnostic Laboratories National Jewish Health

Tilman Koelsch, MD Associate Professor of Radiology National Jewish Health



Dr. Koelsch presenting on Radiologic Evaluation of Pulmonary NTM Infections



Thank you to all the faculty who make this program possible!

Amy Leitman, JD President NTM Info & Research

Ted Marras, MD Associate Professor Director of the Toronto Western Hospital NTM program University of Toronto, Canada

Stacy Martiniano, MD Associate Professor of Pediatrics Children's Hospital of Colorado University of Colorado Hospital

Hilda Metijan, MD, FCCP Associate Professor PCD Clinical Adult Site Director Division of Pulmonary, Critical Care & Sleep Medicine National Jewish Health

John Mitchell, MD

David Endowed Chair in Thoracic Surgery Professor and Chief General Thoracic Surgery University of Colorado Hospital

John Torrence Bronchiectasis and NTM Ambassador COPD Foundation

Kevin Winthrop MD, MPH Professor of Medicine Division of Public Health, Infectious Disease, & Ophthalmology Oregon Health & Science University


"This conference was undoubtedly among the best I have ever attended. The technical content, credentials of presenters, and overall organization of the sessions was excellent. Thank you for the work you do in this field!" - Live in-person provider conference attendee




Dr. Kasperbauer moderating an expert faculty panel




Quantitative Educational Impact Summary: Live Virtual Program




Qualitative Educational Impact Summary: Live Virtual Program



Level 1 Outcomes: Participation by Degree




Level 1 Outcomes: Participation by Specialty




Level 2 Outcomes: Satisfaction

Analysis of evaluation responses related to educational needs Participants rated "strongly agree to agree" for how well the activity:



Level 3/4 Outcomes: Knowledge/Competence



Level 3/4 outcomes were measured by comparing participants' pre- and post-test answers. The attendees' responses to these questions demonstrated that **participants gained knowledge and competence as a result of the activity.**

Overall relative knowledge/competence gain by question from pre- to post-

activity

45%


Overall absolute knowledge/competence gain by question from preto post-activity

24%




Level 3 & 4 Outcomes: Knowledge/Competence Gains by Objective

Learning Objective Knowledge Gain




Learning Objective: Recognize the incidence and distribution of NTM disease.

Q1: Which state in the US has the highest rate of NTM infection?




Learning Objective: Identify the clinical manifestations of NTM disease

Q2: A patient with M. chimaera endocarditis most likely acquired infection from:




Learning Objective: Differentiate the various types of NTM infections.

Q3: Amikacin liposome inhalation suspension is approved by the Federal Drug Administration (FDA) for treatment of which of the following patients?




Learning Objective: Describe the guidelines for the diagnosis and treatment of NTM infections.

Q4: What do the CFF/ECFS consensus guidelines recommend for first-line treatment for macrolide-susceptible, non-cavitary MAC in patients with cystic fibrosis?




Learning Objective: Describe the guidelines for the diagnosis and treatment of NTM infections.

Q5: You have an 80-year-old patient on diltiazem, insulin, and pantoprozole with newly diagnosed pulmonary non-cavitary M. avium infection based on 2 smear negative/ culture positive sputums with moderate cough and fatigue. The CT scan shows only tree-in-bud changes. What diagnosis/treatment is most appropriate at this time?




Learning Objective: Apply the latest evidence to make decisions about pharmacologic and nonpharmacologic management of NTM

Q6: Which medication can cause significant accumulation of rifabutin if given as part of a multidrug regimen for M. avium infection?



Learning Objective: Apply the latest evidence to make decisions about pharmacologic and non-pharmacologic management of NTM

Q7: A 70-year-old male patient grows Mycobacterium kansasii from three out of three sputum specimens. Chest CT scan shows evidence of fibrocavitary changes in the left upper lobe and areas of emphysema. The patient complains of shortness of breath and some weight loss but minimal cough. Which of the following is the most appropriate next step?



Level 4 Outcomes: Competence

Learners reported their confidence on the learning objectives before and after the program (somewhat confident – very confident)

in Confidence: Apply the latest evidence to decisions about 19% pharmacologic and non-pharmacologic management 124% 72% of NTM Describe the guidelines for the diagnosis and 33% treatment of NTM infections 85% 25% Differentiate the various types of NTM infections 76% **Absolute Gain** in Confidence: Identify the clinical manifestations of NTM lung 65% 93% disease 46% Recognize the incidence and distribution of NTM lung 42% 91% disease National Jewish Before Presentations (N=48) ■ After Presentations (N=46)

Relative Gain

Level 4 Outcomes: Competence

An analysis of open-ended comments demonstrates the following changes learners intend to make:

- Management of adverse effects of treatment
- I have gained a lot of knowledge to help address questions I receive on NTM.
- Identifying infection and educating patients on types of Mycobacteria
- Checking genetic changes in organisms, sending more specimens to National Jewish for that reason
- My index of suspicion for NTM lung disease in the patient population which I see has increased dramatically as a result of this conference. Additionally, I have a deeper understanding of the need for expert centers such as National Jewish Health.
- Treatment regimens selected and how to alter regimens based on side effects
- · Attempt to obtain clofazimine and treat in indicated patients
- Use of percussion/expectoration devices
- Management of ALIS side effects and medication side effects
- Focus more on airway clearance




N=47

Evaluation respondents intend to make changes to practice as a result of the activity



Program Evaluation



Program Evaluation

What barriers will the education provided help to address?

- Airway clearance can be done by the patient in their own home with sufficient education
- Medication side effect management strategies
- Insurance authorizations
- For US providers issues about Medicare were undoubtedly helpful
- Patient advocacy
- Issues with patient adherence to airway clearance and medications
- Barriers to obtaining medications and strategies for assisting patients with access

81% N=47


Evaluation respondents reported the activity addressed strategies for overcoming barriers to optimal patient care

What topics would you like more information about in future educational activities?

- Causes of aspiration
- How to navigate the requirements for obtaining clofazamine
- How to overcome medication adverse effects
- More discussion of extra-pulmonary NTM
- More case discussions dealing with MAC refractory to treatment.
- Reviewing complicated cases, in particular patients with multiple comorbidities, drug interactions, etc.
- NTM infections in the non-HIV, non-SOT, immunocompromised patient
- Treatment options for chelonae, abscessus
- Understanding culture report compared to guidelines
- Updates in treatment

Level 5 Outcomes: Performance

71% of follow-up survey respondents stated that their patients have benefited from information they learned in the activity. [N=7]



57% of follow-up survey respondents stated that they have already made changes in practice based on what they learned in the activity. [N=7]

Examples of changes made in practice include:

- · Better awareness of side effects
- Antibiotic education for patients
- Improved knowledge of bronchiectasis on CT scans
- Use of ALIS


86%

Follow-up survey respondents reported the activity helped them address barriers they have recently encountered in practice



Level 5 Outcomes: Performance

Learners reported their confidence on the learning objectives before and after the program, and again at 45-days following the program (somewhat confident – very confident)



Accreditation

National Jewish Health is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The NJH Office of Professional Education produced and accredited this program and adhered to the updated ACCME guidelines.

NJH designates this live activity for a maximum of 13.75 *AMA PRA Category 1 Credits*™.

Provider approved by the California Board of Registered Nursing, Provider Number 12724, for 13.75 contact hours.







National Jewish Health[®] Breathing Science is Life.

NTM Lecture Series for Patients and Families

April 27, 2024

Patient Course Evaluation

After participating in this activity, what changes might you incorporate into your daily life?

- Focus more on nutrition and stress management.
- Do a better job with airway clearance.
- Strength building exercises in addition to cardio.
- Join some of the support groups to chat with other patients about their conditions and what is helping them.
- Continue to do airway clearance with extra care of cleaning devices and being aware of environmental factors.
- Encouraged to persist in being diligent in prescribed therapies.

"Thank you SO much to everyone involved in putting on this seminar. I felt so acknowledged and did not feel like I was talked down to. The physicians put everything into plain language so that it made it easier for us non-health professionals to understand the topics ."

- Patient course attendee

440 In-Person and Virtual

Attendees

99% of attendees reported the conference addressed topics that mattered to them [N=113]



Patient Course Evaluation

What factors make it difficult to follow the treatment plan(s) prescribed by your providers?

- Cost of some of the clearance meds challenge my Coverage D limits.
- Doctors and healthcare providers are not easily available for questions or assistance.
- Making time for the airway clearance.
- I often have side effects from medications. I am always fatigued and have shortness of breath that prevents me from using the nebulizer for medication and saline.
- Extreme fatigue, muscle weakness, nausea and aversion to food.
- · Concern about lab reports and weight loss.

What have you found supports you most in following the treatment plan(s) prescribed by your providers?

- A supportive and creative provider.
- Retreats and conference have helped me a lot.
- NTM Support Group meetings and members.
- Empathy, encouragement, education.
- Having a complete understanding of the mechanisms of disease and the principles behind the recommendations.

"It was truly a wonderful series. My thanks to all who made it happen. The speakers were great, and the talk by John Torrence, who I know through Bronchiectasis and NTM 360, inspired me since he is a person just like me or anyone else who has these lung issues." - Patient attendee

"Once again, it was an extraordinarily helpful conference. As an Emerita Professor at Columbia University, I was deeply impressed with the MDs' emphasis on doing one's best as a patient, but also being tolerant of the difficulties these diseases can cause patients." - Patient attendee

